23andMe has been granted a patent for binding proteins that target human IL-36 cytokines, blocking their signaling pathways. The patent includes specific sequences for anti-IL-36 antibodies. GlobalData’s report on 23andMe gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on 23andMe, was a key innovation area identified from patents.
Anti-il-36 antibody for blocking il-36 signaling pathways
A recently granted patent (Publication Number: US11884719B2) discloses an anti-IL-36 antibody with specific amino acid sequences in its light chain variable domain (VL) and heavy chain variable domain (VH). The antibody is designed to bind to hu-IL-36a, hu-IL-36-ß, and/or hu-IL-36-? with high binding affinity, inhibiting intracellular signals stimulated by these interleukins. The antibody also demonstrates the ability to decrease the release of IL-8 from primary human keratinocytes when stimulated by IL-36a, IL-36ß, and/or IL-36?. Furthermore, the patent includes claims for multispecific antibodies with distinct binding specificities for different IL-36 interleukins, as well as compositions comprising the disclosed antibodies and a pharmaceutically acceptable carrier.
The patent also covers antibodies that exhibit cross-reactivity with IL-36 interleukins in cynomolgus monkeys, highlighting their potential for broader applications. These antibodies are characterized by their binding affinity to cynomolgus monkey IL-36a, IL-36ß, and IL-36?, measured by equilibrium dissociation constant (KD). Additionally, the antibodies described in the patent are designed to decrease intracellular signals stimulated by IL-36a, IL-36ß, or IL-36? by at least 90%, showcasing their potential therapeutic efficacy. The patent further emphasizes the antibodies' ability to inhibit the release of IL-8 from primary human keratinocytes in response to IL-36 interleukins, underscoring their potential as novel therapeutic agents for inflammatory conditions involving IL-36 signaling pathways.
To know more about GlobalData’s detailed insights on 23andMe, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.